Download Image
    
Share
  
Post
GB0139 for COVID-19
1 study with 41 patients
Hospital Icon Control
Hospital Icon GB0139 Serious Outcome Risk
No significant improvements are seen in meta analysis to date.
COVID-19 GB0139 studies. Nov 2025. c19early.org
0 0.5 1 1.5+ All studies -40% Mortality -40% RCTs -40% Late -40% FavorsGB0139 Favorscontrol
Jan 15
2023
 Gaughan et al., American Journal of Respiratory and Critical Care Medicine, doi:10.1164/rccm.202203-0477OC An Inhaled Galectin-3 Inhibitor in COVID-19 Pneumonitis: A Phase Ib/IIa Randomized Controlled Clinical Trial (DEFINE)
40% higher mortality (p=0.7) and 100% longer hospitalization. RCT 41 hospitalized COVID-19 pneumonitis patients showing inhaled GB0139, a galectin-3 inhibitor, was well-tolerated with no treatment-related serious adverse events. There were greater rates of decline in inflammatory markers (CRP, LDH,..